SELLAS Life Sciences Strengthens Cash Reserves and Expands Clinical Pipeline Amid Pivotal 2026 Milestones
Market Chameleon (Fri, 20-Mar 10:05 AM)
SLS009 Shows Potent Activity Against High-Risk AML in Preclinical Data—Broad Efficacy Across Challenging Genetic Subtypes
Market Chameleon (Wed, 18-Mar 7:31 AM)
Enrollment Milestone for SLS009: Phase 2 AML Trial Targets Patients Least Likely to Respond to Standard Therapy
Market Chameleon (Thu, 12-Mar 9:25 AM)
